Has Aaron Nelson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $472 in general payments to Aaron Nelson, MD across 9 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aaron Nelson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aaron Nelson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aaron Nelson, MD

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1750649570

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Amgen at 24.1% of the total. Reporting peaked in 2019 at $250 and has fallen 82.4% since, to $44 in 2024. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MA, where the typical reported total is $583.

$472in general payments, 2019–2025

Across 9 payments — averaging $52.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$114
Dexcom, Inc.$108
Valeritas, Inc.$95
Tandem Diabetes Care, Inc.$77
Insulet Corporation$64
Intuity Medical Inc$14

$2,604in research payments, 2019–2025

Across 15 payments — averaging $173.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Abbott$3K

What the payments were for

Food & beverage$472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	1	$114
Dexcom, Inc.	3	$108
Valeritas, Inc.	1	$95
Tandem Diabetes Care, Inc.	2	$77
Insulet Corporation	1	$64
Intuity Medical Inc	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Prolia$114

How this compares

$472 in reported general payments places this provider in the 45th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$83,727

Medicare patients

318

Services billed

1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	74	$133,438
TrulicityDulaglutide	99	$121,440
JardianceEmpagliflozin	67	$81,436
MounjaroTirzepatide	35	$37,767
FarxigaDapagliflozin Propanediol	26	$29,181
JanuviaSitagliptin Phosphate	21	$18,990
TradjentaLinagliptin	21	$16,686
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	65	$9,208
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	22	$8,589
Novolog FlexpenInsulin Aspart	28	$6,249
HumalogInsulin Lispro	26	$5,302
Nano 2nd Gen Pen NeedlePen Needle, Diabetic	51	$4,291
NovologInsulin Aspart	11	$4,179
Humalog Kwikpen U-100Insulin Lispro	19	$3,691
SynthroidLevothyroxine Sodium	35	$2,678

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Boston

Jason GagliaBoston$2.4M
Vanita ArodaBoston$482K
Michael RosenblattBoston$447K
Steven RussellBoston$445K
Beverly BillerBoston$346K
Christos MantzorosBoston$243K
Augusto Caballero-RoblesBoston$150K
Osama HamdyBoston$117K
Barbara KahnBoston$105K
Naomi FisherBoston$79K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →